• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

初诊大 B 细胞淋巴瘤伴或不伴后续疾病进展的基因组特征。

Genomic Features of Newly Diagnosed Large B-cell Lymphoma with or without Subsequent Disease Progression.

机构信息

Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.

Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

出版信息

Cancer Res Commun. 2024 Nov 1;4(11):2947-2954. doi: 10.1158/2767-9764.CRC-24-0337.

DOI:10.1158/2767-9764.CRC-24-0337
PMID:39392347
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11558615/
Abstract

Genomic features of LBCL that can be detected by clinical laboratory assays may predict for resistance to first-line immunochemotherapy, as well as support the exploration of genomic features as biomarkers of response to therapies which could be offered to patients who experience disease progression.

摘要

LBCL 可通过临床实验室检测到的基因组特征可能预测对一线免疫化疗的耐药性，同时支持将基因组特征作为治疗反应的生物标志物进行探索，这些标志物可提供给经历疾病进展的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7194/11558615/a7c3b4ce121d/crc-24-0337_f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7194/11558615/429354633d3a/crc-24-0337_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7194/11558615/05fc0f6836dd/crc-24-0337_f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7194/11558615/940710bc1eb5/crc-24-0337_f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7194/11558615/a7c3b4ce121d/crc-24-0337_f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7194/11558615/429354633d3a/crc-24-0337_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7194/11558615/05fc0f6836dd/crc-24-0337_f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7194/11558615/940710bc1eb5/crc-24-0337_f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7194/11558615/a7c3b4ce121d/crc-24-0337_f4.jpg

相似文献

1
Genomic Features of Newly Diagnosed Large B-cell Lymphoma with or without Subsequent Disease Progression.初诊大 B 细胞淋巴瘤伴或不伴后续疾病进展的基因组特征。
Cancer Res Commun. 2024 Nov 1;4(11):2947-2954. doi: 10.1158/2767-9764.CRC-24-0337.
2
Analysis of Histologic, Immunohistochemical and Genomic Features of Large B Cell Lymphoma Tumors May Predict Response to Polatuzumab Vedotin Based Therapy in Patients With Relapsed/Refractory Disease.对大B细胞淋巴瘤肿瘤的组织学、免疫组织化学和基因组特征进行分析，可能预测复发/难治性疾病患者对泊洛妥珠单抗维达替尼治疗的反应。
Clin Lymphoma Myeloma Leuk. 2025 Jan;25(1):45-51. doi: 10.1016/j.clml.2024.08.010. Epub 2024 Sep 6.
3
Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases.脾边缘区淋巴瘤进展为大B细胞淋巴瘤：12例病例系列描述
Am J Surg Pathol. 2001 Oct;25(10):1268-76. doi: 10.1097/00000478-200110000-00007.
4
Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms: A Multiparameter Study of a Rare and Aggressive Entity.TdT+ 大 B 细胞淋巴瘤的突变景观支持其与 B 淋巴母细胞肿瘤的区分：一种罕见且侵袭性实体的多参数研究。
Am J Surg Pathol. 2022 Jan 1;46(1):71-82. doi: 10.1097/PAS.0000000000001750.
5
Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment Resistance.弥漫性大 B 细胞淋巴瘤与原发性治疗抵抗相关的分子特征。
Hematol Oncol. 2025 Jan;43(1):e70006. doi: 10.1002/hon.70006.
6
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis.一线弥漫性大 B 细胞淋巴瘤中 BCL2 表达可识别预后不良的患者人群。
Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):267-278.e10. doi: 10.1016/j.clml.2020.11.004. Epub 2020 Nov 10.
7
Challenges in Assessing MYC Rearrangement in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type.原发性皮肤弥漫性大B细胞淋巴瘤，腿部型中MYC重排评估的挑战
Am J Surg Pathol. 2020 Mar;44(3):424-427. doi: 10.1097/PAS.0000000000001412.
8
Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses.复发性弥漫性大B细胞淋巴瘤在早期和晚期复发之间呈现出不同的基因组图谱。
Oncotarget. 2016 Dec 20;7(51):83987-84002. doi: 10.18632/oncotarget.9793.
9
The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.塞尔维亚东南部接受免疫化疗的弥漫性大B细胞非霍奇金淋巴瘤患者生存中Myd88 L265P突变、临床及免疫组化预后因素的重要性
J BUON. 2016 Sept-Oct;21(5):1259-1267.
10
CD38, CD39, and BCL2 differentiate disseminated forms of high-grade B-cell lymphomas in biological fluids from Burkitt lymphoma and diffuse large B-cell lymphoma.CD38、CD39和BCL2可区分伯基特淋巴瘤和弥漫性大B细胞淋巴瘤生物体液中高级别B细胞淋巴瘤的播散形式。
Cytometry B Clin Cytom. 2024 Nov;106(6):448-464. doi: 10.1002/cyto.b.22208. Epub 2024 Sep 19.

本文引用的文献

1
TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era.TP53 突变可预测当代新诊断侵袭性 B 细胞淋巴瘤患者的不良预后。
Blood Adv. 2023 Dec 12;7(23):7243-7253. doi: 10.1182/bloodadvances.2023011384.
2
Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma.复发时间与弥漫性大 B 细胞淋巴瘤的独特进化动力学相关。
J Clin Oncol. 2023 Sep 1;41(25):4164-4177. doi: 10.1200/JCO.23.00570. Epub 2023 Jun 15.
3
Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
弥漫性大 B 细胞淋巴瘤的遗传亚型简化算法。
Signal Transduct Target Ther. 2023 Apr 10;8(1):145. doi: 10.1038/s41392-023-01358-y.
4
Clinical efficacy and tumour microenvironment influence of decitabine plus R-CHOP in patients with newly diagnosed diffuse large B-Cell lymphoma: Phase 1/2 and biomarker study.地西他滨联合R-CHOP方案治疗初诊弥漫性大B细胞淋巴瘤患者的临床疗效及肿瘤微环境影响：1/2期及生物标志物研究
Clin Transl Med. 2021 Dec;11(12):e584. doi: 10.1002/ctm2.584.
5
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.泊洛妥珠单抗联合化疗治疗未经治疗的弥漫性大 B 细胞淋巴瘤
N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14.
6
Impact of Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.CD19 嵌合抗原受体 T 细胞治疗治疗的大 B 细胞淋巴瘤中基因组改变的影响。
J Clin Oncol. 2022 Feb 1;40(4):369-381. doi: 10.1200/JCO.21.02143. Epub 2021 Dec 3.
7
Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.Fimepinostat (CUDC-907) 在复发/难治性弥漫性大 B 细胞和高级别 B 细胞淋巴瘤患者中的应用：一项 2 期试验及探索性生物标志物分析的报告。
Br J Haematol. 2021 Oct;195(2):201-209. doi: 10.1111/bjh.17730. Epub 2021 Aug 2.
8
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.RO6870810 是一种新型溴结构域和末端外蛋白抑制剂的 I 期研究，在患有 NUT 癌、其他实体瘤或弥漫性大 B 细胞淋巴瘤的患者中进行。
Br J Cancer. 2021 Feb;124(4):744-753. doi: 10.1038/s41416-020-01180-1. Epub 2020 Dec 14.
9
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.塔西美替尼治疗复发或难治性滤泡性淋巴瘤患者的疗效：一项开放标签、单臂、多中心、2 期临床试验。
Lancet Oncol. 2020 Nov;21(11):1433-1442. doi: 10.1016/S1470-2045(20)30441-1. Epub 2020 Oct 6.
10
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.HDAC3的选择性抑制靶向合成易感性并激活淋巴瘤中的免疫监视。
Cancer Discov. 2020 Mar;10(3):440-459. doi: 10.1158/2159-8290.CD-19-0116. Epub 2020 Jan 8.